These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36495880)

  • 1. Bimekizumab in psoriatic arthritis: a great leap forward?
    Queiro R
    Lancet; 2023 Jan; 401(10370):2-3. PubMed ID: 36495880
    [No Abstract]   [Full Text] [Related]  

  • 2. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab safe and effective for psoriatic arthritis.
    McHugh J
    Nat Rev Rheumatol; 2023 Feb; 19(2):64. PubMed ID: 36596926
    [No Abstract]   [Full Text] [Related]  

  • 4. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
    Oliveira DG; Faria R; Torres T
    Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.
    Wells LE; Evans T; Hilton R; Wine Lee L; Ruth N
    Pediatr Dermatol; 2019 May; 36(3):384-385. PubMed ID: 30811618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB
    Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
    Ali Z; Matthews R; Al-Janabi A; Warren RB
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab for the treatment of psoriatic arthritis.
    Chandler DJ; Bewley A
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):111-21. PubMed ID: 24494794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 10. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
    Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
    Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
    Shaw CA; Kole LCS; Elewski BE
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e431-e432. PubMed ID: 31220373
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis.
    Kimura U; Kinoshita A; Sekigawa I; Takamori K; Suga Y
    J Dermatol; 2012 Dec; 39(12):1071-2. PubMed ID: 22506677
    [No Abstract]   [Full Text] [Related]  

  • 13. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab in the treatment of psoriatic arthritis.
    Lespessailles E; Toumi H
    Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
    Gordon KB; Ruderman EM
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S85-91. PubMed ID: 16488334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
    Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real-world setting.
    Gkanti V; Dalamaga M; Papadavid E
    Int J Dermatol; 2023 Jan; 62(1):e31-e34. PubMed ID: 36087047
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
    Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab safe and effective for AS and PsA in long-term trials.
    Phillips R
    Nat Rev Rheumatol; 2022 Sep; 18(9):494. PubMed ID: 35922551
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.